# Josep Tabernero

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/josep-tabernero/

## Facts

| Field | Value |
| --- | --- |
| Citations | 129,154 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 146 |
| i10-index | 823 |
| Last Known Institution | Hebron University |
| OpenAlex ID | https://openalex.org/A5015190461 |
| ORCID iD | https://orcid.org/0000-0002-2495-8139 |
| Works | 2,697 |

## Researcher papers

Showing 12 of 14.

- [The landscape of somatic copy-number alteration across human cancers](https://scholariq.org/papers/the-landscape-of-somatic-copy-number-alteration-across-human-cancers/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer](https://scholariq.org/papers/the-8q24-cancer-risk-variant-rs6983267-shows-long-range-interaction-with-myc-in/)
- [Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer](https://scholariq.org/papers/final-results-from-prime-randomized-phase-iii-study-of-panitumumab-with-folfox4/)
- [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://scholariq.org/papers/genomic-and-transcriptomic-profiling-expands-precision-cancer-medicine-the/)
- [Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with/)
- [Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer](https://scholariq.org/papers/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal/)
- [Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study](https://scholariq.org/papers/fruquintinib-versus-placebo-in-patients-with-refractory-metastatic-colorectal/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Hebron University](https://scholariq.org/institutions/hebron-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.